Skip to Main Content

Advertisement

Skip Nav Destination

Issues

TOP READS

J Immunol (2023) 210 (2): 117.

BRIEF REVIEWS

J Immunol (2023) 210 (2): 119–125.
J Immunol (2023) 210 (2): 126–133.

CLINICAL AND HUMAN IMMUNOLOGY

J Immunol (2023) 210 (2): 135–147.

  • We identify an lncRNA, HAFML, which promotes the aggression of RA FLS.

  • HAFML regulates RA FLS invasion by combining with HuR to control APPL2 mRNA stability.

IMMUNE REGULATION

J Immunol (2023) 210 (2): 148–157.

  • B-1b cell–intrinsic IFNAR expression promotes TI-2 Ab responses.

  • MPL/TDCM adjuvant effects are independent of type 1 IFN.

  • MPL/TDCM promotes TI-2 Ab responses by innate B cells.

J Immunol (2023) 210 (2): 158–167.

  • The presence of Fab glycans hinders IgG interaction with hFcRn in a cell-based assay.

  • Membrane context likely plays a key role, which conventional assays do not show.

  • Impaired placental transfer further illustrates the hindering effect of Fab glycans.

INFECTIOUS DISEASE AND HOST RESPONSE

J Immunol (2023) 210 (2): 168–179.

  • Susceptibility and loss of 1° and 4° memory CD8 T cells are similar after sepsis.

  • Primary memory CD8 T cells become overrepresented over time in sepsis survivors.

  • Sepsis leads to changes in subset composition of the memory CD8 T cell pool.

INNATE IMMUNITY AND INFLAMMATION

J Immunol (2023) 210 (2): 180–190.

  • JMJD3 is required for acute pancreatitis in mouse models.

  • mtDNA contributes to lung injury through the STING/TLR9-NF-κB-JMJD3-TNF-α pathway.

MOLECULAR AND STRUCTURAL IMMUNOLOGY

J Immunol (2023) 210 (2): 191–203.

  • gcTBK1_tv3 inhibits the replication and infection of GCRV.

  • gcTBK1_tv3 promotes the degradation of NS80 or NS38.

  • gcTBK1_tv3 impairs the production of cytoplasmic VIBs.

TUMOR IMMUNOLOGY

J Immunol (2023) 210 (2): 204–215.

  • AL008 induces SIRPα degradation and immune activation through FcγR2A engagement.

  • AL008 promotes T cell proliferation more effectively than anti-CD47 Abs.

  • In vivo, AL008 demonstrated antitumor activity alone or with anti–PD-L1.

Close Modal

or Create an Account

Close Modal
Close Modal